PT  - JOURNAL ARTICLE
AU  - Medina Torres, Maria Isabel
AU  - Macias, Adrian Santos
AU  - Mateo, Inmaculada Luque
AU  - Muñoz, Javier Nieto
TI  - #36497 Botulinum toxin infiltration as an option for treatment of persistent headache associated with COVID-19. Case report
AID  - 10.1136/rapm-2023-ESRA.365
DP  - 2023 Sep 01
TA  - Regional Anesthesia & Pain Medicine
PG  - A199--A199
VI  - 48
IP  - Suppl 1
4099  - http://rapm.bmj.com/content/48/Suppl_1/A199.1.short
4100  - http://rapm.bmj.com/content/48/Suppl_1/A199.1.full
SO  - Reg Anesth Pain Med2023 Sep 01; 48
AB  - Please confirm that an ethics committee approval has been applied for or granted: Not relevant (see information at the bottom of this page) Application for ESRA Abstract Prizes: I apply as an Anesthesiologist (Aged 35 years old or less)Background and Aims Different descriptions of long COVID have already been proposed, and the most common description includes symptoms lasting for over three months after the first symptom onset. One of the most frequent symptoms identified, besides fatigue and dyspnoea, is a new daily persistent headache. We describe a case of persistent headache associated with COVID-19, which had a poor response to pharmacological treatment. The patient scored a pain of 8 points in Visual Analog Scale (VAS). It was a widespread—affecting frontal, temporal, and occipital area—pulsating quality headache that worsened with mild physical activity.Methods Since Botulinum toxin type A has been used to treat chronic migraine for over a decade, we decided to try this therapeutic option after proving that the response to local anesthetics was positive. She responded satisfactorily to bilateral greater occipital nerve block and infiltration of the frontal and temporal muscles with local anesthetic and corticosteroids, with an improvement during approximately 48 hours. Two weeks later, we administered by ultrasound guidance 20 IU of botulinum toxin near the greater occipital nerve, and performed a mapping with botulinum toxin by administering it at different points: both trapezius, splenius, frontal muscles, bilateral orbicularis and bilateral temporal and parietal musclesResults After seven days, the patient reported improvement of the symptoms (VAS 3) that were still present one month later.Conclusions In conclusion, we propose that botulinum toxin can be a therapeutic option for persistent headaches associated with COVID-19. However, future research studies are required to clarify this possibility.